Skip to main content
SpringerLink
Log in

Nausea and Vomiting

  • Chapter
  • First Online:
The MASCC Textbook of Cancer Supportive Care and Survivorship

  • 1248 Accesses

Abstract

The introduction of two new classes of antiemetics, the 5 hydroxytryptamine 3 receptor antagonists (5HT3 RAs) and the neurokinin1 receptor antagonists (NK1 RAs) have revolutionised the treatment of post-chemotherapy acute and delayed nausea and vomiting, and this in turn has decreased the incidence of anticipatory emesis. Triple antiemetic therapy combining a 5HT3 RA and NK1 RA with dexamethasone is recommended by MASCC for the prevention of nausea and vomiting, associated with chemotherapy of high emetic potential and the anthracycline/cyclophosphamide (AC) regimen. Nausea is not as well controlled as vomiting but is a symptom that has multiple associated symptoms to treat. There are few differences between 5HT3 RAs, except palonosetron with a longer half-life and better control of delayed emesis with non-AC chemotherapy of moderate emetic potential, where it is the recommended 5HT3 RA. Single agents are recommended for the prevention of emesis in patients receiving chemotherapy of low emetic potential and who have a prior history of emesis while no antiemetic prevention is recommended prior to chemotherapy of minimal emetic potential. Older antiemetics such as dopamine antagonists and adjuvant drugs such as the benzodiazepines can be used for emesis that is refractory to the above antiemetic regimens. More research is needed into the optimal antiemetic regimens for children receiving chemotherapy, patients receiving high dose chemotherapy and those being treated with radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Andrews PI, Naylor RJ, Joss RA. Neuropharmacology of vomiting and its relevance to anti emetic therapy. Consensus and controversies. Support Care Cancer. 1998;6:197–203.

    Article  PubMed  CAS  Google Scholar 

  2. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high dose cisplatin. J Clin Oncol. 1985;3:1379–1384.

    PubMed  CAS  Google Scholar 

  3. Morrow GR. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst. 1982;68: 585–593.

    PubMed  CAS  Google Scholar 

  4. Olver IN. The development of future research strategies form reviewing antiemetic trials for chemotherapy induced emesis. Rev Recent Clin Trials. 2006;1:61–66.

    Article  PubMed  CAS  Google Scholar 

  5. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support Care Cancer. 2005;13:80–84.

    Article  PubMed  Google Scholar 

  6. Coates A, Abraham S, Kaye SB, et al. On the receiving end – patient perceptions of the side effects of cancer chemotherapy. Eur J Cancer. 1983;19:203–208.

    Article  CAS  Google Scholar 

  7. De Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, van Beurden V, Stoter G. Patient perceptions of side effects of chemotherapy: the influence of 5HT antagonists. Br J Cancer. 1997;76: 1055–1061.

    Article  PubMed  Google Scholar 

  8. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Supportive Care Cancer. 1997;5:307–313.

    Article  CAS  Google Scholar 

  9. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100:2261–2268.

    Article  PubMed  Google Scholar 

  10. Molassiotis A, Saunders MP, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer. 2008;16:201–208

    Article  PubMed  CAS  Google Scholar 

  11. Guttuso T, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet. 2003;361:1703–1705.

    Article  PubMed  CAS  Google Scholar 

  12. Ryan JL, Heckler C, Dakhil SR, et al. Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomised, double-blind, placebo-controlled clinical trial of 644 cancer patients. Proc Am Soc Clin Oncol. 2009; Abstract 9511.

    Google Scholar 

  13. Gralla RJ. Metoclopramide. A review of antiemetic trials. Drugs. 1983;25(Suppl 1): 63–73.

    Article  PubMed  Google Scholar 

  14. Olver IN, Wolf MM, Laidlaw C, et al. A randomized double blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as an antiemetic for cancer chemotherapy. Eur J Cancer. 1992;28A:798–1802.

    Google Scholar 

  15. Martin BR, Wiley JL. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol. 2004;2:305–316.

    PubMed  CAS  Google Scholar 

  16. Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cisplatin-induced vomting. Cancer Chemother Pharmacol. 1981;7:11–14.

    Article  PubMed  CAS  Google Scholar 

  17. Olver I, Paska W, Depierre A, et al on behalf of the Ondansetron Delayed Emesis Study Group. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol. 1996;7:945–952.

    Article  PubMed  CAS  Google Scholar 

  18. Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med. 2000;342: 1554–1559.

    Article  Google Scholar 

  19. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358: 2482–2494.

    Article  PubMed  CAS  Google Scholar 

  20. Malik I, Khan WA, Qazilbash M, et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol. 1995;18:170–175.

    Article  PubMed  CAS  Google Scholar 

  21. Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5HT3 and 5-HT6 receptors by olanzapine. Eur J Pharmacol. 2001;430:341–349.

    Article  PubMed  CAS  Google Scholar 

  22. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2007;15:1285–1291.

    Article  PubMed  Google Scholar 

  23. du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer. 1992;28:450–457.

    Article  PubMed  Google Scholar 

  24. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med. 2001;111(Suppl 8A):106S–112S.

    Article  PubMed  Google Scholar 

  25. Antiemetic Subcommittee of the Multinational Association of supportive care in Cancer (MASCC). Prevention of chemotherapyand radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol. 1998;9:1022–1029.

    Google Scholar 

  26. Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007;15:1023–1033.

    Article  PubMed  CAS  Google Scholar 

  27. Blackwell CP, Harding SM. The clinical pharmacology of Ondan­setron. Eur J Cancer Clin Oncol. 1989;25(Suppl 1):S21-4–S25-7.

    Google Scholar 

  28. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932–2947.

    Article  PubMed  CAS  Google Scholar 

  29. Rojas C, Stathis M, Thomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5HT3 receptor. Anesth Analg. 2008;107:469–478.

    Article  PubMed  CAS  Google Scholar 

  30. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570–1577.

    Article  PubMed  CAS  Google Scholar 

  31. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al.; 99-04 Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473–2482.

    Google Scholar 

  32. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;9:1441–1449.

    Article  Google Scholar 

  33. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10: 115–124.

    Article  PubMed  CAS  Google Scholar 

  34. Einhorn LH, Rapoport B, Koeller J, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer. 2005;13:112–116.

    Article  PubMed  Google Scholar 

  35. Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F, Bianchini C, Perrone T. Palonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer. 2009;17:205–209.

    Article  PubMed  Google Scholar 

  36. Cartmell AD, Ferguson S, Yanagihara R, et al. Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5HT3 receptor antagonist. Proc Am Soc Clin Oncol. 2003; 22:756, Abstract 3041.

    Google Scholar 

  37. Hargreaves R. Imaging substance P receptors (NKr) in the living human brain using positron emission tomography. J Clin Psychiatry. 2002;63(Suppl 11):18–24.

    PubMed  CAS  Google Scholar 

  38. Olver I, Shelukar S, Thompson KC. Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomed. 2007;2:13–18.

    Article  CAS  Google Scholar 

  39. Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004;32: 1287–1292.

    Article  PubMed  CAS  Google Scholar 

  40. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin-1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74:17–24.

    Article  PubMed  CAS  Google Scholar 

  41. Blum R, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther. 2003;25:1407–1419.

    Article  PubMed  CAS  Google Scholar 

  42. Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005;55:609–616.

    Article  PubMed  CAS  Google Scholar 

  43. Depré M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol. 2005;61:34–36.

    Google Scholar 

  44. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21: 4112–4119.

    Article  PubMed  CAS  Google Scholar 

  45. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–3098.

    Article  PubMed  CAS  Google Scholar 

  46. de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NKl antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003;21:4105–4119.

    Article  PubMed  CAS  Google Scholar 

  47. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000–1006.

    Article  PubMed  CAS  Google Scholar 

  48. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–2830.

    Article  PubMed  CAS  Google Scholar 

  49. Rapoport B, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4):423–431.

    Article  PubMed  Google Scholar 

  50. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol. 2006;4:403–408.

    PubMed  CAS  Google Scholar 

  51. Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol. 2007;47:834–840.

    Article  PubMed  CAS  Google Scholar 

  52. Arpornwirat W, Albert I, Hansen V.L., et. al. Multicenter, randomized, doubleblind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CONV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol. 2006; ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 8512.

    Google Scholar 

  53. Navari RM. Casopitant, a neurokinin-1 receptor antagonist with antiemetic and antinausea activities. Curr Opin Investig Drugs. 2008;9;774–785.

    PubMed  CAS  Google Scholar 

  54. Grunberg SM, Aziz Z, Shaharyar A, et al. Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol. 2008;26(Suppl 15):Abstract 9540.

    Google Scholar 

  55. Grunberg SM, Rolski J, Strausz J, et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:549–558.

    Article  PubMed  CAS  Google Scholar 

  56. Herrstedt J, Apornwirat W, Shaharyar A, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol. 2009;27: 5363–5369.

    Article  PubMed  CAS  Google Scholar 

  57. Grunberg SM, Hesketh PJ and Carides AD, et al. Relationships between the incidence and control of cisplatin-induced acute vomiting and delayed vomiting: Analysis of pooled data from two phase III studies of the NK-1 antagonist aprepitant. Proc Am Soc Clin Oncol. 2003; 22:2931a.

    Google Scholar 

  58. Herrstedt J, Roila F. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol. 2009;20(Suppl 4):156–158.

    PubMed  Google Scholar 

  59. Paul B, Trovato JA, Thompson J, et al. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract. 2010 Mar;16(1):45–51. Epub 2009 Jun 12.

    Google Scholar 

  60. Horiot JC, Aapro M. Treatment implications for radiation-induced nausea and vomiting in specific patient groups. Eur J Cancer. 2004; 40:979–987.

    Article  PubMed  Google Scholar 

  61. Dupuis LL, Nathan PC. Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines. Pediatr Drugs. 2010;12(1):51–61. doi: 10.2165/11316190-000000000-00000.

    Article  Google Scholar 

  62. Gore L, Chawla S, Petrilli A, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer. 2009;52(2):242–247.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Sydney Medical School, Cancer Council Australia, Surry Hills, Sydney, NSW, 2010, Australia

    Ian N. Olver

Authors
  1. Ian N. Olver
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian N. Olver .

Editor information

Editors and Affiliations

  1. Clinical Professor, Cancer Coucil Australia, University of Sydney Medical School, Surry Hills, 2010, New South Wales, Australia

    Ian N. Olver

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Society for Imaging Informatics in Medicine

About this chapter

Cite this chapter

Olver, I.N. (2010). Nausea and Vomiting. In: Olver, I. (eds) The MASCC Textbook of Cancer Supportive Care and Survivorship. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-1225-1_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1225-1_24

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-1224-4

  • Online ISBN: 978-1-4419-1225-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation